TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

As previously announced, Patricia L. Bitar resigned from her position as the Chief Financial Officer of TRACON Pharmaceuticals, Inc. (the “Company”), effective June 15, 2018.

Effective upon Ms. Bitar’s resignation, Charles P. Theuer, M.D., Ph.D., the Company’s Chief Executive Officer, was appointed as the Company’s principal financial officer and principal accounting officer. Dr. Theuer’s biographical and compensation information is available in the Company’s prior filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed March 1, 2018, and its Definitive Proxy Statement, filed April 25, 2018.

Item 5.02 Submission of Matters to a Vote of Security Holders.

On June13, 2018, TRACON Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders at its corporate headquarters located at 4350 La Jolla Village Drive, Suite 800, San Diego, California 92122 at 8:00a.m. pacific time (the “2018 Annual Meeting”).The Company had 29,731,331 shares of common stock outstanding and entitled to vote as of April 20, 2018, the record date for the 2018 Annual Meeting.At the 2018 Annual Meeting, 20,850,070 shares of common stock of the Company were present or represented by proxy.

At the 2018 Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 25, 2018.

At the 2018 Annual Meeting, the Company’s stockholders:

(1)elected Dr. Charles P. Theuer, William R. LaRue and Paul Walker as directors of the Company to hold office until the 2021 Annual Meeting of Stockholders; and

(2)ratified the appointment of Ernst& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018.

The following sets forth detailed information regarding the final certified results of the voting with respect to each matter voted upon at the 2018 Annual Meeting:

Proposal 1. Election of Directors

Proposal 2. Ratification of the selection of Independent Registered Public Accounting Firm

About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.